Camilla Soenderby
Direttore/Membro del Consiglio presso BB BIOTECH AG
Profilo
Camilla Soenderby is currently a Director at Affibody Medical AB.
She also holds the position of Non-Executive Director at F2G Ltd., Director at BB Biotech AG, and Director at Abivax SA. Previously, she worked as the Head-Product Strategy Officer at Takeda Pharmaceutical Co., Ltd.
from 2019 to 2020.
She also held positions as Head-Global Product Strategy at Shire France SAS, General Manager at Schering-Plough Ltd.
(Taiwan), and General Manager at AbbVie SAS (France).
Ms. Soenderby completed her undergraduate degree at the University of Copenhagen.
Posizioni attive di Camilla Soenderby
| Società | Posizione | Inizio |
|---|---|---|
| BB BIOTECH AG | Direttore/Membro del Consiglio | 21/03/2024 |
| ABIVAX | Direttore/Membro del Consiglio | 01/03/2024 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Direttore/Membro del Consiglio | 15/09/2021 |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Camilla Soenderby
| Società | Posizione | Fine |
|---|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01/01/2020 |
Schering-Plough Ltd. (Taiwan)
 Schering-Plough Ltd. (Taiwan) Medical DistributorsDistribution Services Part of Merck & Co., Inc., Schering-Plough Ltd. (Taiwan) is a Taiwanese company that sells and supplies pharmaceutical products. The company is based in Taipei, Taiwan. | Corporate Officer/Principal | - |
AbbVie SAS (France)
 AbbVie SAS (France) Medical DistributorsDistribution Services Part of AbbVie, Inc., AbbVie SAS (France) is a health endowment fund that supports general and innovative health projects in therapeutic areas such as virology, oncology, immunology, and neuroscience. The company is based in Rungis, France. The French company encourages actors in the field to improve the patient's journey and trust them. The company was founded in 2012. Sylvie Gregoire Huguel has been the CEO of the company since 2018. | Corporate Officer/Principal | - |
Shire France SAS
 Shire France SAS Pharmaceuticals: MajorHealth Technology Shire France SA manufactures pharmaceutical products. The firm offers prescriptions and proprietary drugs. It specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, and genetic diseases. The company was founded in 1997 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Formazione di Camilla Soenderby
| University of Copenhagen | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| BB BIOTECH AG | Finance |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| ABIVAX | Health Technology |
| Aziende private | 5 |
|---|---|
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Shire France SAS
Shire France SAS Pharmaceuticals: MajorHealth Technology Shire France SA manufactures pharmaceutical products. The firm offers prescriptions and proprietary drugs. It specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, and genetic diseases. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Schering-Plough Ltd. (Taiwan)
Schering-Plough Ltd. (Taiwan) Medical DistributorsDistribution Services Part of Merck & Co., Inc., Schering-Plough Ltd. (Taiwan) is a Taiwanese company that sells and supplies pharmaceutical products. The company is based in Taipei, Taiwan. | Distribution Services |
AbbVie SAS (France)
AbbVie SAS (France) Medical DistributorsDistribution Services Part of AbbVie, Inc., AbbVie SAS (France) is a health endowment fund that supports general and innovative health projects in therapeutic areas such as virology, oncology, immunology, and neuroscience. The company is based in Rungis, France. The French company encourages actors in the field to improve the patient's journey and trust them. The company was founded in 2012. Sylvie Gregoire Huguel has been the CEO of the company since 2018. | Distribution Services |
- Borsa valori
- Insiders
- Camilla Soenderby
